Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
Date:10/7/2010

MILAN, Oct. 7 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

"It's been almost five years since the approval of Nexavar in its first indication, advanced kidney cancer, and since that time the continuum of development in other areas has produced clinically significant findings, leading to a second approval in unresectable liver cancer," said Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. "Our dedication to the development of Nexavar is demonstrated by the array of data being presented at this year's ESMO Congress as well as the ongoing clinical trial program evaluating Nexavar in a variety of treatment settings and patient types."

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 95 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators.

Important Safety Considerations For Patien
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch America" ... to provide this review of the Company,s recent achievements ... "Over this past year, we achieved many of ... proud to say that Monarch America is in a ... ever been," stated Eric Hagen , CEO of ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3ResMed To Announce Second Quarter 2015 Results 2
... Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today ... credit facilities of its wholly owned subsidiary Valeant ... by the Company.  The proposed $1.7 billion senior ... a $200 million revolving facility and a $1.5 ...
... 20, 2011 – Ingenuity® Systems, a leading ... life science researchers, today announced the addition ... from miRecords , plus thousands of ... peer-reviewed literature. The newly added content supplements ...
Cached Medicine Technology:Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities 2Ingenuity Announces New Additional MicroRNA Content to Complement First-of-its-Kind MicroRNA Filtering Capability in IPA 2
(Date:12/22/2014)... AZ (PRWEB) December 22, 2014 Parker ... the absolute best in Arizona home contracting services reports ... regard to its quality services in 2014. As a ... since the early 1970s, Parker and Sons is a ... reliability. The company works side-by-side with other top quality ...
(Date:12/21/2014)... 2014 Recently, BambooFlooringChina.com, a famous bamboo ... bamboo flooring collection , and launched a bamboo flooring ... is valid until Jan. 30, 2015. , According to ... the hardest bamboo flooring available today; it has a ... traditional teak hardwoods. Strand woven bamboo is made by ...
(Date:12/21/2014)... BellasDress.com offers a wide range of ... it announces its BellasDress Christmas Sale , offering ... store. , BellasDress is a famous online supplier of ... through a series of promotions. The dress experts of ... , “We are proud of offering high quality wedding ...
(Date:12/21/2014)... 2014 When families in Coral Gables get ... call? The new answer is Lice Troopers . Located ... their newest treatment center will be the new go-to resource ... without the use of harmful chemicals or pesticides. ... 1, 2015. Like the company’s first clinic (located at 1005 ...
(Date:12/21/2014)... York (PRWEB) December 21, 2014 ... other product liability claims involving a class of ... continue to move forward in a federal multidistrict ... District of California, Bernstein Liebhard LLP reports. According ... has established a data cut-off date of February ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:BellasDress.com Announces its BellasDress Christmas Sale 2Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4
... Jan. 6 Compass Group North America of,Charlotte, ... Harwood Heights,Illinois-based KIMCO Corporation, a provider of support ... Through the acquisition, KIMCO,becomes a wholly owned subsidiary ... division of Compass Group North America focused on ...
... very troubling for patients. Often, they are misdiagnosed and ... As a clinician, it is imperative to recognize symptoms ... and follow up to ensure patient compliance. To make ... management of psychotic and mood disorders, Current Psychiatry ...
... iTMP Technology, a,pioneering smartphone hardware and software developer, ... poised to bring unparalleled,health and fitness capabilities to Apple(R) ... SMHEART LINK and its iPhone fitness apps this,week at ... SMHEART LINK is a wireless bridge that enables ...
... Jan. 6 The International Health, Racquet and Sportsclub ... anyone looking to live a happier, healthier, longer life ... one of the best medicines we have to help ... President and CEO of IHRSA. "During times of stress ...
... Launches New Web Site Resource for FamiliesPHILADELPHIA, Jan. 6 ... of Philadelphia presents a unique new web site designed to ... of healthy and fun recipes, as well as useful nutrition ... and more. The Nutrition in the ...
... During 2009, millions of Americans will undergo unnecessary ... mind-altering drugs that fail to eliminate their back pain ... source of most back pain, says pioneering pain specialist, ... Marcus.Back pain is the most common disabling pain experienced ...
Cached Medicine News:Health News:Compass Group North America Acquires KIMCO Corporation 2Health News:New SMHEART LINK(TM) Technology Allows iPhones to Double as Fitness Monitors 2Health News:New SMHEART LINK(TM) Technology Allows iPhones to Double as Fitness Monitors 3Health News:One Simple Step to Obtain Health, Happiness, and Longevity in 2009 2Health News:One Simple Step to Obtain Health, Happiness, and Longevity in 2009 3Health News:One Simple Step to Obtain Health, Happiness, and Longevity in 2009 4Health News:New Kid Friendly Online Cookbook to Encourage Healthy Eating 2Health News:New Kid Friendly Online Cookbook to Encourage Healthy Eating 3Health News:Unnecessary Spinal Surgery Will Waste Billions of Dollars in 2009 and Patients Will Continue to Suffer Unless the Primary Cause of Most Back Pain is Treated, Says Pain Specialist Norman Marcus, M.D. 2Health News:Unnecessary Spinal Surgery Will Waste Billions of Dollars in 2009 and Patients Will Continue to Suffer Unless the Primary Cause of Most Back Pain is Treated, Says Pain Specialist Norman Marcus, M.D. 3Health News:Unnecessary Spinal Surgery Will Waste Billions of Dollars in 2009 and Patients Will Continue to Suffer Unless the Primary Cause of Most Back Pain is Treated, Says Pain Specialist Norman Marcus, M.D. 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: